Active, not recruitingPhase 1NCT02546661

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Studying Hinman syndrome

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: Thomas Powles, MBBS, MRCP, MD, MD
Barts Cancer Center, Barts and The London School of Medicine and Denistry
Intervention: AZD4547(drug)
Enrollment: 117 target
Eligibility: 18-130 years · All sexes
Timeline: 2016 – 2026

Study locations (23)

Research Site, Los Angeles, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Fort Myers, Florida, United States
Research Site, New York, New York, United States
Research Site, Cleveland, Ohio, United States
Research Site, Nashville, Tennessee, United States
Research Site, Edmonton, Alberta, Canada
Research Site, Vancouver, British Columbia, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Bordeaux, France
Research Site, Caen, France
Research Site, Lyon, France
Research Site, Marseille, France
Research Site, Saint-Herblain, France
+8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02546661 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome →

← Back to all trials